I found this recent China Daily article about Chinese pharmaceutical companies and their partnerships with multinational pharmaceutical companies interesting.
"Hisun got a breakthrough in China's pharmaceutical industry by taking a controlling stake in the joint venture with Pfizer, the world's largest drug-maker by sales. Hisun has a 51 percent share in Hisun-Pfizer Pharmaceuticals Co, with a total investment of $295 million and registered capital of $250 million. Pfizer holds the remaining stock..."The negotiations (between Hisun and Pfizer) took more than a year. It's really tough with rounds and rounds of bargains and discussions. We got stuck on the controlling stake," said a senior executive of Hisun, speaking anonymously."
Provectus' process to consummate a regional license deal in China has been informative. It think its nearing its end.
No comments:
Post a Comment